Released: Tuesday 26th September 2023

Team expansion on the cards as biotechnology company eyes international growth

A Dundee company which pioneers revolutionary, market-leading biotechnology is gearing up to
expand its team as it seeks to fulfil ambitious international growth plans.

Cellexus International Ltd (Cellexus) has strengthened its commitment to the city and is poised to
recruit at least two additional staff as it expands its corporate horizons into a growing number of
overseas markets.

From the company’s research, development and manufacturing base in Dundee, Cellexus provides
its CellMaker range of the only single use, purely airlift bioreactor systems on the market to
customers across the life sciences sector, including biotech laboratories and academic settings. The
patented system is fully customisable to ensure bespoke solutions for customers thus offering a
faster route to market than incumbent technologies.

More than a decade of development sits behind the brand which was acquired by its current
management in 2017 and is headed by CEO Gavin Hands. Cellexus currently employs a team of eight
specialists with that number expected to hit double digits by the end of this year.

With sales now evenly split between UK and overseas markets, recent installations for the
flourishing bioreactor manufacturing company have taken its products to the likes of Hungary, Texas
and South Korea for the first time. These successes now mean that Cellexus systems are already in
place in 11 countries across three continents, and engagement is ongoing with 23 countries through
active accounts and enquiries.

Having been named as a finalist in the Small Business and Technology categories of this year’s
Courier Business Awards, the company’s global presence is set for imminent further expansion at
forthcoming trade events in Barcelona at CPHI and Philadelphia at the World AMR Congress where
Cellexus will exhibit for the first time.

Commenting on how the company is gearing up for growth, Gavin Hands said: “We are now having
conversations in every European country and looking at new applications where there is growth and
scalability such as phage, viral vector, protein and antibody manufacturing.

“In order to help us follow through on these target applications, it is important that we add to our
pool of expertise to ensure that we are correctly positioned for what promises to be an exciting
phase in our corporate journey.”

To find out more, visit www.cellexus.com